MabionCD20 is a monoclonal antibody originally developed by Mabion as a biosimilar candidate to MabThera and Rituxan therapies
The safety profile was described as manageable, though not without notable toxicities
Approved as a web-based pre-diagnostic tool for suspected rare diseases and classified as a Class A (non-sterile and non-measuring) medical device
Initiative by National Health Authority aimed at accelerating automated claims processing under Ayushman Bharat Pradhan Mantri Jan Arogya Yojana
Digital platform records over 1.34 crore beneficiary registrations with QR-enabled MCH cards and real-time monitoring features
As per GlobalData, CARsgen’s satri-cel could mark a major breakthrough in solid tumor treatment as competition intensifies
This is an exciting and meaningful milestone for GRIN Therapeutics
More than 3,500 participants will join the nationwide AI-focused hackathon hosted as Indian Institute of Science
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
Discussions will focus on how private space stations can improve access, repeatability and commercial feasibility for advanced biotech experiments
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
